hrcak mascot   Srce   HID

Sažetak sa skupa

Terlipressine-induced ischemic skin necrosis and malignant arrhythmia: case report

Ana Magdalena Glas ; School of Medicine University of Zagreb
Ivana Karla Franić ; School of Medicine University of Zagreb
Ena Janči ; School of Medicine University of Zagreb
Stela Hrkač ; School of Medicine University of Zagreb

Puni tekst: engleski, pdf (65 KB) str. 0-0 preuzimanja: 16* citiraj
APA 6th Edition
Glas, A.M., Franić, I.K., Janči, E. i Hrkač, S. (2019). Terlipressine-induced ischemic skin necrosis and malignant arrhythmia: case report. Liječnički vjesnik, 141 (suppl.1), 0-0. Preuzeto s https://hrcak.srce.hr/225513
MLA 8th Edition
Glas, Ana Magdalena, et al. "Terlipressine-induced ischemic skin necrosis and malignant arrhythmia: case report." Liječnički vjesnik, vol. 141, br. suppl.1, 2019, str. 0-0. https://hrcak.srce.hr/225513. Citirano 28.01.2020.
Chicago 17th Edition
Glas, Ana Magdalena, Ivana Karla Franić, Ena Janči i Stela Hrkač. "Terlipressine-induced ischemic skin necrosis and malignant arrhythmia: case report." Liječnički vjesnik 141, br. suppl.1 (2019): 0-0. https://hrcak.srce.hr/225513
Harvard
Glas, A.M., et al. (2019). 'Terlipressine-induced ischemic skin necrosis and malignant arrhythmia: case report', Liječnički vjesnik, 141(suppl.1), str. 0-0. Preuzeto s: https://hrcak.srce.hr/225513 (Datum pristupa: 28.01.2020.)
Vancouver
Glas AM, Franić IK, Janči E, Hrkač S. Terlipressine-induced ischemic skin necrosis and malignant arrhythmia: case report. Liječnički vjesnik [Internet]. 2019 [pristupljeno 28.01.2020.];141(suppl.1):0-0. Dostupno na: https://hrcak.srce.hr/225513
IEEE
A.M. Glas, I.K. Franić, E. Janči i S. Hrkač, "Terlipressine-induced ischemic skin necrosis and malignant arrhythmia: case report", Liječnički vjesnik, vol.141, br. suppl.1, str. 0-0, 2019. [Online]. Dostupno na: https://hrcak.srce.hr/225513. [Citirano: 28.01.2020.]

Sažetak
Terlipressine is a long-acting synthetic analogue of vasopressine used in the treatment of complications of liver cirrhosis such as hepatorenal syndrome (HRS) or variceal bleeding. Some of the most common adverse effects are abdominal cramps, headaches, bradycardia, and peripheral vasoconstriction. Despite being rare, malignant arrhythmia and skin necrosis can lead to fatal outcome. We report a female patient with HRS type 1 who received terlipressine intravenously for 7 days. Since there was no evidence of clinical improvement, on the 6th day norepinephrine was introduced as a second vasopressor. The day after the second drug was added, bullous skin changes occurred on her extremities and trunk. Those changes quickly progressed to necrosis and repetitive polymorphic VT with prolonged QTc intervals were also noted. Because of the severe adverse effects terlipressine was discontinued which led to an improvement of the skin lesions and cessation of malignant arrhythmia. Despite treatment, HRS led to multiple organ failure subsequently causing death of the patient. Although it is very effective in the treatment of HRS, terlipressine carries certain risk of side effects. Potentially lethal adverse effects are rare but nevertheless, it is important to know them in order to be able to recognise them as soon as possible.

Ključne riječi
terlipressin, hepatorenal syndrome, adverse effects, skin necrosis

Hrčak ID: 225513

URI
https://hrcak.srce.hr/225513

Posjeta: 45 *